Controversial Juul E-cigarettes Removed from Market by FDA

Jun.24.2022

All Juul e-cigarette products are being taken off the market by the FDA due to potentially harmful chemicals.

The US Food and Drug Administration has removed all electronic cigarette products manufactured by controversial company Juul, but not for the reasons one might expect.

The US Food and Drug Administration (FDA) has announced its plans to remove Juul products from the market. This decision is based on toxicology data and the potential risk of harmful chemicals that have been found to seep out from the company's proprietary pods, rather than their appeal to young people.

This move by the FDA is the most significant action taken to date against a major tobacco company and could spell disaster for the Juul brand.

#Juul #FDA #E-cigarette #E-cigarettes and Tobacco #E-cigarette Market

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting

The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.

Nov.24 by 2FIRSTS.ai

ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most

In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.

Oct.21

Juul’s San Francisco Headquarters May Be Sold as Debt Talks Advance

Real estate firm Affinius Capital is in talks to sell the loan tied to Juul’s San Francisco headquarters, with Madison Capital emerging as a potential buyer. If completed, the deal could lead to a change in ownership six years after Juul first acquired the building, signaling continued asset adjustments amid regulatory pressure.

Oct.23

UK’s Nationwide Crackdown Seizes 111,000 Illegal Vapes in “Machinize 2” Operation

UK police have carried out a nationwide crackdown under Operation Machinize 2, targeting illegal vapes, counterfeit goods, and grey-market businesses. Raids on more than 2,700 premises led to 924 arrests and the seizure of 111,000 illegal vapes, 70kg of cannabis, 4.5m cigarettes, and £10.7m in proceeds.

Nov.11 by 2FIRSTS.ai